A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Throughout our history, we have advanced the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our immune medicine platform applies our proprietary technologies to read the diverse genetic code of a patient’s immune system and understand precisely how the immune system detects and treats disease in that patient. We capture these insights in our dynamic clinical immunomics database and related antigen annotations, which are underpinned by computational biology and machine learning, and use them to develop and commercialize clinical products and services that can be tailored to the needs of individual patients.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 277M | 277M | 179M | 170M | 185M | 154M |
| Net Income | -59M | -59M | -159M | -225M | -200M | -207M |
| EPS | $-0.39 | $-0.39 | $-1.08 | $-1.56 | $-1.40 | $-1.48 |
| Free Cash Flow | -49M | -49M | -99M | -167M | -200M | -254M |
| ROIC | -12.4% | -17.5% | -47.6% | -51.3% | -34.0% | -34.3% |
| Gross Margin | 74.2% | 74.2% | 59.7% | 55.6% | 68.7% | 68.1% |
| Debt/Equity | 0.98 | 0.98 | 1.10 | 0.74 | 0.50 | 0.19 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -57M | -57M | -163M | -227M | -200M | -209M |
| Operating Margin | -20.6% | -20.6% | -90.8% | -133.3% | -108.0% | -135.4% |
| ROE | -27.2% | -28.2% | -78.7% | -73.0% | -43.1% | -34.3% |
| Shares Outstanding | 153M | 153M | 148M | 144M | 143M | 140M |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |||
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 56M | 85M | 98M | 154M | 185M | 170M | 179M | 277M | 277M |
| Gross Margin | 64.7% | 73.8% | 77.1% | 68.1% | 68.7% | 55.6% | 59.7% | 74.2% | 74.2% |
| R&D | 39M | 71M | 116M | 142M | 142M | 122M | 103M | 94M | 94M |
| SG&A | 20M | 30M | 50M | 75M | 89M | 84M | 73M | 73M | 73M |
| EBIT | -50M | -78M | -153M | -209M | -200M | -227M | -163M | -57M | -57M |
| Op. Margin | -89.4% | -92.1% | -155.3% | -135.4% | -108.0% | -133.3% | -90.8% | -20.6% | -20.6% |
| Net Income | -46M | -70M | -146M | -207M | -200M | -225M | -159M | -59M | -59M |
| Net Margin | -83.3% | -81.8% | -148.6% | -134.3% | -108.0% | -132.3% | -89.1% | -21.5% | -21.5% |
| Non-Recurring | 0 | 840K | 0 | 0 | 0 | 25M | 9.2M | 2.0M | 2.0M |
| Returns on Capital | |||||||||
| ROIC | -15.0% | -11.4% | -18.8% | -34.3% | -34.0% | -51.3% | -47.6% | -17.5% | -12.4% |
| ROE | N/A | -12.2% | -19.7% | -34.3% | -43.1% | -73.0% | -78.7% | -28.2% | -27.2% |
| ROA | -13.9% | -7.6% | -13.1% | -22.4% | -23.4% | -34.1% | -29.6% | -11.3% | -11.6% |
| Cash Flow | |||||||||
| Op. Cash Flow | -32M | 205M | -150M | -193M | -184M | -156M | -95M | -46M | -46M |
| Free Cash Flow | -39M | 194M | -168M | -254M | -200M | -167M | -99M | -49M | -49M |
| Owner Earnings | -49M | 184M | -183M | -250M | -260M | -241M | -168M | -115M | -115M |
| CapEx | 6.3M | 11M | 19M | 62M | 16M | 11M | 3.7M | 3.0M | 3.0M |
| Maint. CapEx | 6.0M | 7.8M | 8.5M | 14M | 21M | 22M | 19M | 18M | 18M |
| Growth CapEx | 318K | 3.4M | 10M | 48M | 0 | 0 | 0 | 0 | 0 |
| D&A | 6.0M | 7.8M | 8.5M | 14M | 21M | 22M | 19M | 18M | 18M |
| CapEx/OCF | N/A | 5.5% | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 11M | 13M | 25M | 43M | 55M | 63M | 54M | 51M | 51M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||||
| Net Debt | N/A | -540M | -544M | -241M | -265M | -117M | 1.2M | -12M | 145M |
| Cash & Equiv. | 55M | 97M | 123M | 139M | 90M | 65M | 48M | 70M | 70M |
| Long-Term Debt | N/A | 37M | 37M | N/A | 125M | 131M | 132M | 127M | 127M |
| Debt/Equity | -0.12 | 0.06 | 0.19 | 0.19 | 0.50 | 0.74 | 1.10 | 0.98 | 0.98 |
| Interest Coverage | N/A | N/A | N/A | N/A | -47.2 | -16.5 | -14.0 | -4.8 | -4.8 |
| Equity | -258M | 571M | 743M | 604M | 464M | 308M | 203M | 219M | 219M |
| Total Assets | 333M | 912M | 1.1B | 923M | 857M | 661M | 539M | 513M | 513M |
| Total Liabilities | 30M | 341M | 373M | 319M | 393M | 353M | 337M | 288M | 288M |
| Intangibles | 14M | 12M | 10M | 8.5M | 6.8M | 5.1M | 3.4M | 1.7M | 1.7M |
| Retained Earnings | -296M | -365M | -512M | -719M | -919M | -1.1B | -1.3B | -1.4B | -1.4B |
| Working Capital | 158M | 534M | 622M | 289M | 452M | 322M | 186M | 210M | 210M |
| Current Assets | 181M | 613M | 727M | 403M | 562M | 410M | 284M | 300M | 300M |
| Current Liabilities | 23M | 78M | 105M | 114M | 110M | 88M | 98M | 90M | 90M |
| Per Share Data | |||||||||
| EPS | -3.67 | -1.01 | -1.11 | -1.48 | -1.40 | -1.56 | -1.08 | -0.39 | -0.39 |
| Owner EPS | -0.39 | 1.33 | -1.39 | -1.78 | -1.82 | -1.67 | -1.14 | -0.76 | -0.76 |
| Book Value | -2.04 | 4.10 | 5.64 | 4.31 | 3.25 | 2.14 | 1.37 | 1.43 | 1.43 |
| Cash Flow/Share | -0.26 | 1.48 | -1.14 | -1.38 | -1.29 | -1.08 | -0.64 | -0.30 | -0.27 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 126.3M | 139.2M | 131.7M | 140.1M | 143.0M | 144.4M | 147.7M | 152.6M | 152.6M |
| Valuation | |||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -37.3 |
| P/FCF | N/A | 21.0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 7.1 | 10.8 | 6.1 | 2.1 | 2.5 | 4.6 | 11.6 | 10.1 |
| Price/Sales | N/A | 57.3 | 52.6 | 36.5 | 8.3 | 5.8 | 3.5 | 6.2 | 8.0 |
| FCF Yield | N/A | 4.8% | -2.1% | -6.9% | -20.3% | -21.7% | -10.6% | -1.9% | -2.2% |
| Market Cap | N/A | 4.1B | 8.0B | 3.7B | 988M | 770M | 929M | 2.5B | 2.2B |
| Avg. Price | N/A | 35.00 | 39.28 | 40.25 | 10.70 | 6.86 | 4.23 | 11.29 | 14.53 |
| Year-End Price | N/A | 29.27 | 61.00 | 26.26 | 6.91 | 5.33 | 6.29 | 16.70 | 14.53 |
Adaptive Biotechnologies Corp passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 65.3%. At current prices, the estimated annualized return to fair value is -15.1%.
Adaptive Biotechnologies Corp (ADPT) has a 5-year average return on invested capital (ROIC) of -36.9%. This is below average and may indicate limited pricing power.
Adaptive Biotechnologies Corp (ADPT) has a market capitalization of $2.2B. It is classified as a mid-cap stock.
Adaptive Biotechnologies Corp (ADPT) does not currently pay a regular dividend.
Adaptive Biotechnologies Corp (ADPT) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Adaptive Biotechnologies Corp (ADPT) reported annual revenue of $277 million in its most recent fiscal year, based on SEC EDGAR filings.
Adaptive Biotechnologies Corp (ADPT) has a net profit margin of -21.5%. The company is currently unprofitable.
Adaptive Biotechnologies Corp (ADPT) generated $-49 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Adaptive Biotechnologies Corp (ADPT) has a debt-to-equity ratio of 0.98. This indicates moderate leverage.
Adaptive Biotechnologies Corp (ADPT) reported earnings per share (EPS) of $-0.39 in its most recent fiscal year.
Adaptive Biotechnologies Corp (ADPT) has a return on equity (ROE) of -28.2%. A negative ROE may indicate losses or negative equity.
Adaptive Biotechnologies Corp (ADPT) has a 5-year average gross margin of 65.3%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 8 years of financial data for Adaptive Biotechnologies Corp (ADPT), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Adaptive Biotechnologies Corp (ADPT) has a book value per share of $1.43, based on its most recent annual SEC filing.
No recent press releases.